A new shot for RSV shot for infants is in short supply
A new shot for infants against RSV is in short supply, and U.S. health officials are telling doctors they should prioritize giving the drug to babies at the highest risk of severe disease
NEW YORK (AP) — A new shot for infants against RSV is in short supply, and U.S. health officials told doctors they should prioritize giving the drug to babies at the highest risk of severe disease.
Infants less than 6 months who have chronic lung disease or other underlying conditions should be given priority, the Centers for Disease Control and Prevention told doctors in a Monday evening advisory.
RSV, or respiratory syncytial virus, is a common cause of coldlike symptoms that can be dangerous for young children. A seasonal virus, it's being widely reported in the southern United States and is expected to continue to spread over the next month or two.
The new, one-time shot is a lab-made antibody that helps the immune system fight off the virus. Sold under the brand name Beyfortus, the drug was developed by AstraZeneca and Sanofi.
